Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
St. John's Wort
Accession Number
DB01323
Type
Small Molecule
Groups
Approved, Investigational, Nutraceutical
Description
Not Available
Synonyms
  • Common st johnswort flowering top
  • Common st. john's wort flowering top
  • Common st. john's wort herb
  • Common st. johnswort flowering top
  • Guanyejinsitao
  • Hyperici herba
  • Hypericum nachitschevanicum flowering top
  • Hypericum perforatum flowering top
  • Hypoxis hemerocallidea root extract
  • Klamath weed flowering top
  • Klamathweed flowering top
  • Saint johns wort
  • St john's wort
  • St Johns Wort
  • St. john’s wort
  • St. johns wort
  • St. johnswort flowering top
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethical Herbals ST. John's WortTabletOralAshbury Research CorporationNot applicableNot applicableCanada
Ethical Herbals ST. John's WortTabletOralAshbury Research CorporationNot applicableNot applicableCanada
Felis Forte Capsules 425mgCapsuleOralRhoxalpharma IncNot applicableNot applicableCanada
Felis Tablets 250mgTabletOralRhoxalpharma IncNot applicableNot applicableCanada
ST. John's WortCapsuleOralNew Vision Nutritionals Company1998-10-012002-11-20Canada
ST. John's WortCapsuleOralBioprint Laboratories Ltd2000-06-082001-07-31Canada
ST. John's WortCapsuleOralPharmavite1999-01-202004-07-20Canada
ST. John's WortCapsuleOralWampole Brands2003-02-012004-06-29Canada
ST. John's WortCapsuleOralSwiss Herbal Remedies Ltd.1998-02-202008-08-15Canada
ST. John's WortCapsuleOralWn Pharmaceuticals Ltd.1998-12-152006-08-08Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dynamiclear RapidSt. John's Wort (0.5 mg/1mL) + Calendula officinalis flower (0.5 mg/1mL) + Cupric sulfate pentahydrate (40 mg/1mL)LiquidTopicalRX PHARMA-PACK, INC.2019-02-06Not applicableUs
Dynamiclear RapidSt. John's Wort (0.5 mg/1mL) + Calendula officinalis flower (0.5 mg/1mL) + Cupric sulfate pentahydrate (40 mg/1mL)LiquidTopicalRX PHARMA-PACK, INC.2019-02-06Not applicableUs
Nite-capsSt. John's Wort (20 mg) + Hops (40 mg) + Valerian (40 mg)CapsuleOralFlora Manufacturing And Distributing Ltd.1991-12-312002-09-10Canada
S. R. FormulaSt. John's Wort (200 mg) + Valerian (133.2 mg)LiquidOralMorinda Canada2002-01-142006-07-12Canada
Categories
UNII
UFH8805FKA
CAS number
84082-80-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with St. John's Wort.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with St. John's Wort.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with St. John's Wort.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when St. John's Wort is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when St. John's Wort is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with St. John's Wort.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when St. John's Wort is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when St. John's Wort is combined with 5-methoxy-N,N-dimethyltryptamine.
6-Deoxyerythronolide BThe metabolism of St. John's Wort can be decreased when combined with 6-Deoxyerythronolide B.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference

Trevor Percival Castor, Theodore Abraham Tyler, Richard Joseph Student, "Methods for making Hypericum fractions and St. John's Wort products." U.S. Patent US6291241, issued December, 1998.

US6291241
General References
  1. Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6. [PubMed:12153829]
  2. Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19. [PubMed:16423519]
  3. Authors unspecified: Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14. [PubMed:11939866]
External Links
PubChem Substance
46507869
PharmGKB
PA164924486
Drugs.com
Drugs.com Drug Page
Wikipedia
St_John%27s_wort
ATC Codes
N06AX25 — Hyperici herba
AHFS Codes
  • 92:01.00* — Herbs and Natural Products

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableVA Drug Interactions [VA Drug Interaction]1
1CompletedOtherDrug-drug Interaction Study1
1CompletedPreventionHepatitis C Viral Infection1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentAnxiety Disorders / Major Depressive Disorder (MDD)1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentNicotine Dependence / Smoking1
2CompletedTreatmentObsessive Compulsive Disorder (OCD)1
2CompletedTreatmentPhobic Disorders1
2TerminatedSupportive CareCancer, Breast / Hot Flushes1
2, 3CompletedTreatmentAnxiety Disorders / Mental Health1
3CompletedTreatmentAtypical Depression1
3CompletedTreatmentRaynaud's Phenomenon1
3RecruitingDiagnosticPeritoneal Carcinomatosis1
3TerminatedTreatmentPain1
3WithdrawnTreatmentAdult Solid Tumor / Cancer, Breast / Head and Neck Carcinoma / Kidney and Urinary Cancer / Male Reproductive Cancer / Thorax and Respiratory Cancer1
4CompletedDiagnosticPain1
4CompletedTreatmentHealthy Adults / Nootropic Potential of Hypericum and Alprazolam / Subclinical Anxious Adults1
4CompletedTreatmentHealthy Volunteers1
Not AvailableCompletedNot AvailableVA Drug Interactions [VA Drug Interaction]1
Not AvailableCompletedTreatmentContraception1
Not AvailableCompletedTreatmentDepression1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableWithdrawnTreatmentAcute Coronary Syndromes (ACS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Guna Inc.
  • Pekana Naturheilmittel GmbH
  • Weleda Inc.
Dosage forms
FormRouteStrength
LiquidTopical
CapsuleOral
LiquidOral
TabletOral
LiquidOral
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wenk M, Todesco L, Krahenbuhl S: Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004 Apr;57(4):495-9. [PubMed:15025748]
  2. Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
  3. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
  2. Rahimi R, Abdollahi M: An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):691-708. doi: 10.1517/17425255.2012.680886. [PubMed:22606944]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604. [PubMed:11180019]

Drug created on June 30, 2007 11:20 / Updated on November 11, 2019 06:50